All manuscripts
Publications NK Cells G-Rex®24 Well Plate

Adaptive single- KIR+NKG2C+ NK cells expanded from select superdonors show potent missing- self reactivity and efficiently control HLA- mismatched acute myeloid leukemia

Published Journal Journal for ImmunoTherapy of Cancer

Share
No image preview

Overview

This study describes the ADAPT-NK cell product derived from superdonors. The expansion protocol involved co-culturing CD3/CD19-depleted PBMCs with feeder cells in G-Rex® 24 plates for 11 days to generate high numbers of adaptive NK cells.

What this paper found

Adaptive NKG2C+ NK cells carrying a single self-KIR, expanded from selected CMV-seropositive superdonors, killed HLA-C/KIR-mismatched leukemia cells efficiently and controlled acute myeloid leukemia in mice. Using CD3/CD19-depleted cryopreserved donor cells and irradiated K562 feeders expressing HLA-E, a GMP-compliant 11-day protocol produced a median 470-fold expansion, with some donors exceeding 1000-fold. On day 11, a median 91% of NK cells were NKG2C+ and 81% expressed a single self-KIR, while fewer than 20% expressed NKG2A. The cells largely kept their adaptive transcriptional signature without signs of exhaustion. In NSG mice bearing HL-60 leukemia, a single dose of 5 × 10^6 mismatched cells gave substantially better leukemia control by day 35 than matched cells. Adding a CD16/IL-15/CD33 tri-specific engager improved killing of resistant primary AML blasts.

Note: Preclinical study in cell lines, primary AML samples and mice. The authors note that the aggressive growth of the HL-60 mouse model precludes comprehensive survival analyses.

The selective expansion of adaptive NK cells from a mixed NK population avoids any need for GMP-grade selection or editing procedures and therefore reduces the complexity of culturing. — Alvaro Haroun-Izquierdo, Marianna Vincenti, Herman Netskar, Hanna van Ooijen, Bin Zhang, Laura Bendzick, Minoru Kanaya, Pouria Momayyezi, Shuo Li, Merete Thune Wiiger, Hanna Julie Hoel, Silje Zandstra Krokeide, Veronika Kremer, Geir Tjonnfjord, Stéphanie Berggren, Kristina Wikström, Pontus Blomberg, Evren Alici, Martin Felices, Björn Önfelt, Petter Höglund, Bahram Valamehr, Hans-Gustaf Ljunggren, Andreas Björklund, Quirin Hammer, Lise Kveberg, Frank Cichocki, Jeffrey S Miller, Karl-Johan Malmberg, Ebba Sohlberg, Journal for ImmunoTherapy of Cancer

Study details

Authors
Alvaro Haroun-Izquierdo, Marianna Vincenti, Herman Netskar, Hanna van Ooijen, Bin Zhang, Laura Bendzick, Minoru Kanaya, Pouria Momayyezi, Shuo Li, Merete Thune Wiiger, Hanna Julie Hoel, Silje Zandstra Krokeide, Veronika Kremer, Geir Tjonnfjord, Stéphanie Berggren, Kristina Wikström, Pontus Blomberg, Evren Alici, Martin Felices, Björn Önfelt, Petter Höglund, Bahram Valamehr, Hans-Gustaf Ljunggren, Andreas Björklund, Quirin Hammer, Lise Kveberg, Frank Cichocki, Jeffrey S Miller, Karl-Johan Malmberg, Ebba Sohlberg
Institution
Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden · Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital and University of Oslo, Oslo, Norway · Department of Applied Physics, Science for Life Laboratory, KTH Royal Institute of Technology, Stockholm, Sweden · Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA · Department of Hematology, Oslo University Hospital and K.G. Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway · Vecura, Karolinska Center for Cell Therapy Clinical Research Center, Karolinska University Hospital, Stockholm, Sweden · Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden · Department of Microbiology, Tumour and Cell Biology, Karolinska Institutet, Stockholm, Sweden · Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden · Fate Therapeutics Inc, La Jolla, California, USA · Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Stockholm, Sweden
Journal
Journal for ImmunoTherapy of Cancer
Year
2022
PMID / PMC
PMID: 36319065 · PMC
G-Rex® model(s)
G-Rex®24 Well Plate
Cell type(s)
NK Cells
Application area
Hematologic malignancy
Study phase
Preclinical

How G-Rex® was used

CD3/CD19-depleted PBMC from selected superdonors were co-cultured with irradiated HLA-E-expressing K562 feeder cells at a 1:2 ratio in G-Rex®24 plates (Wilson Wolf), seeded at 0.5 × 10^6 total cells/cm². The cultures ran for 11 days in GMP-grade Stem Cell Growth Medium with 10% human AB serum, 2 mM L-glutamine and 100 IU/mL IL-2, with a 60% medium exchange on day 7 and IL-2 added on days 4, 7 and 10. This expansion step produced the ADAPT-NK cell product, with a median 470-fold expansion of adaptive NK cells.

Explore related

Full citation

Haroun-Izquierdo A, Vincenti M, Netskar H, et al. Adaptive single-KIR+NKG2C+ NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia. J Immunother Cancer. 2022;10(11):e005577.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →